Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Paris Cedex 15, France Clinical Trials

A listing of Paris Cedex 15, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (15) clinical trials

Planning Your Everyday Life in Virtual Reality : a Study in Schizophrenia;

Patients with schizophrenia , who visit frenquently day-care or day-care activities clinics, often experience difficulties of daily living and cognitive deficits. Living independently is a key for recovery. Cognitive remediation is a therapy which reduces deficit and improves daily living. Nowadays no program exists targeting neurocognitive functions in virtual reality ...

Phase N/A

0.0 miles

Learn More »

Evaluation of Covered Stents Versus Bare Metal Stents for Endovascular Treatment of Chronic Ischemia Mesenteric Disease.

Chronic Mesenteric Ischemia (CMI) is defined by one or more arterial digestive lesions, responsible for severe mesenteric symptoms. The clinical presentation of CMI is characterized by postprandial abdominal pain and weight loss, leading to severe malnutrition. It is a frequent pathology which affects preferentially the elderly patients of female sex ...

Phase N/A

0.0 miles

Learn More »

Robotic Low Rectum Anterior Resection

The laparoscopic approach for laparoscopic total mesorectal excision (L-TME) results improved short-term outcomes and provides a clearer intraoperative view compared with the open approach in a deep and narrow pelvis. Preliminary results from the COLOR II trial confirmed improved patient recovery and similar safety, same resection margins and completeness of ...

Phase N/A

0.0 miles

Learn More »

BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation

Blinatumomab (BLINCYTO) is a bi-specific T-cell engaging (BiTE) antibody construct that transiently links CD3-positive T cells to CD19-positive B-cells, inducing T-cell activation and subsequent lysis of tumor cells. The investigators propose to evaluate the efficacy, safety and tolerability of blinatumomab administered after R-CHOP debulking therapy in patients with Richter Syndrome ...

Phase

0.0 miles

Learn More »

Determinant of the Risk of the Becoming Frail in the Non-dependent Elederly

Detailed Description: Definition: Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures. (Limit: 32,000 characters) Example Sudden out-of-hospital cardiac arrest ...

Phase N/A

1.61 miles

Learn More »

A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This ...

Phase

1.81 miles

Learn More »

Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers

The project focuses on the progranulin (PGRN) gene mutation, one of the most frequent genetic forms of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD). FTD is the second commonest cause of degenerative dementia in presenium after Alzheimer's disease. Behavioral and cognitive impairments progressively lead to dementia. Two major pathological ...

Phase N/A

1.81 miles

Learn More »

Whole Exome Sequencing of Familial and Pediatric Forms of Vasculitis

The FAMILYVASC study is a prospective observational study which will aim to identify susceptibility loci and genes for systemic vasculitis risk in patients with familial or pediatric forms of vasculitis. Genetic analysis based on whole exome sequencing will be carried out through salivary DNA.

Phase N/A

2.12 miles

Learn More »

A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors

The study will enroll approximately 20 participants to achieve approximately 15 PK-evaluable participants for assessment. This study will consist of 2 parts: Part A of the study will evaluate the effect of repeat-dose administration of brigatinib on the single-dose PK of midazolam. Part B of the study is exploratory and ...

Phase

2.4 miles

Learn More »

Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Patients with previously treated, HPV-induced, stage II or III invasive pelvic cancer and who are currently in post-treatment follow-up will be included. These patients will be followed up during 30 months (2.5 years) (if no relapse occurred before) with ctDNA detection performed at each hospital visit. At each visit, clinical, ...

Phase N/A

2.48 miles

Learn More »